NetScientific PLC (AIM:NSCI) says its portfolio company, PDS Biotechnology Corporation (NASDAQ:PDSB) (Nasdaq: PDSB), made good progress through 2021, hitting a number of milestones.
Ilian Iliev, NetScientific chief executive, said: "PDS has continued the steady progress and build-out of the business, progressing multiple clinical applications of the Versamune platform in immuno-oncology and infectious disease vaccines.
“The company's careful planning and successful fund-raise in 2021 - in which NetScientific participated - has positioned PDS well to weather market volatility, and continue to progress its clinical trials pipeline."
For the year ended December 31, 2021, PDS' net loss was approximately US$16.9mln, or $0.66 per basic share and diluted share, compared to a net loss of approximately US$14.8mln.